Health Catalyst, Inc. (NASDAQ:HCAT) Stock Has Average Target Price of $2.45

Key Points

• Analysts have a “Hold” consensus on Health Catalyst, with seven hold, three buy and one sell rating. The average 12-month price target is $2.45, above the stock’s reported $1.73 price.
• Several firms recently lowered their targets, including Canaccord Genuity to $1.80, Wells Fargo to $1.50 and Citigroup to $2.00, reflecting cautious sentiment.
• CEO Simeon Kohl purchased 59,000 shares for approximately $105,610, while institutional investors own about 85% of the company. The company beat quarterly EPS and revenue estimates but continues to report substantial net losses.

Shares of Health Catalyst, Inc. (NASDAQ:HCAT - Get Free Report) have been assigned an average recommendation of "Hold" from the eleven research firms that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and three have issued a buy rating on the company. The average 1-year target price among analysts that have covered the stock in the last year is $2.45.

HCAT has been the topic of a number of research analyst reports. Canaccord Genuity Group restated a "hold" rating and set a $1.80 price target (down from $3.00) on shares of Health Catalyst in a research report on Thursday, August 20th. Wells Fargo & Company cut their price objective on Health Catalyst from $1.75 to $1.50 and set an "equal weight" rating for the company in a research report on Thursday, August 13th. Citigroup reduced their price objective on Health Catalyst from $2.50 to $2.00 and set a "neutral" rating on the stock in a research note on Tuesday, August 11th. Finally, Weiss Ratings upgraded Health Catalyst from a "sell (e+)" rating to a "sell (d-)" rating in a report on Tuesday, July 28th.

Insiders Place Their Bets

In related news, CEO Simeon Kohl acquired 59,000 shares of the stock in a transaction on Monday, September 14th. The stock was purchased at an average price of $1.79 per share, for a total transaction of $105,610.00. Following the transaction, the chief executive officer owned 2,856,385 shares of the company's stock, valued at $5,112,929.15. The trade was a 2.11% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 19.40% of the company's stock.

Institutional Trading of Health Catalyst

Several hedge funds have recently modified their holdings of HCAT. BlackRock Inc. acquired a new position in Health Catalyst during the 2nd quarter worth $3,654,000. Palogic Value Management L.P. acquired a new stake in shares of Health Catalyst in the 2nd quarter valued at $9,796,000. Hsbc Holdings PLC acquired a new stake in shares of Health Catalyst in the 2nd quarter valued at $809,000. Squarepoint Ops LLC raised its position in shares of Health Catalyst by 1,214.8% during the second quarter. Squarepoint Ops LLC now owns 400,210 shares of the company's stock worth $796,000 after acquiring an additional 369,772 shares during the last quarter. Finally, Headlands Technologies LLC bought a new stake in shares of Health Catalyst during the second quarter worth $131,000. 85.00% of the stock is owned by institutional investors.

Health Catalyst Stock Performance

Shares of NASDAQ:HCAT opened at $1.73 on Thursday. The company has a debt-to-equity ratio of 1.51, a current ratio of 2.70 and a quick ratio of 2.70. The business's fifty day moving average price is $1.81 and its two-hundred day moving average price is $1.63. Health Catalyst has a fifty-two week low of $0.96 and a fifty-two week high of $3.62. The stock has a market capitalization of $130.20 million, a price-to-earnings ratio of -0.47 and a beta of 1.53.

Health Catalyst (NASDAQ:HCAT - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.03 by $0.01. The company had revenue of $70.49 million during the quarter, compared to analysts' expectations of $69.09 million. Health Catalyst had a negative return on equity of 1.83% and a negative net margin of 90.61%. As a group, analysts predict that Health Catalyst will post -0.18 EPS for the current fiscal year.

About Health Catalyst

Health Catalyst, Inc is a healthcare technology and data analytics company that helps healthcare organizations use data to improve clinical outcomes, operational performance and financial results. The company provides software, data management capabilities and professional services designed to support hospitals, health systems, medical groups and other healthcare providers.

Its offerings include the Health Catalyst Data Operating System, which integrates and organizes data from disparate clinical, financial and operational systems, as well as analytics applications for areas such as quality improvement, population health, cost management and care delivery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.